SOUTH SAN FRANCISCO, Calif. — August 13, 2025 — Leads & Copy — CytomX Therapeutics, Inc. (Nasdaq: CTMX) has provided an update on its CX-2051 Phase 1 study, addressing recent social media posts. Enrollment is substantially complete, with 73 colorectal cancer patients enrolled to date, and the company is on track to provide a data update in Q1 2026. The CTMX-2051-101 study remains active, with patients continuing to be dosed with CX-2051 across all expansion doses.
According to Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX, patient safety is the top priority as they continue to advance CX-2051 for the treatment of CRC. Dose expansions at 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg doses, administered every three weeks (Q3W), have each enrolled approximately 20 patients as planned.
A single Grade 5 treatment-related acute kidney injury occurred in a patient with a complex medical history, including a solitary kidney. The event, believed to be secondary to nausea, vomiting, and diarrhea, was promptly reported to the FDA on July 18, 2025, after the company became aware of it on July 11, 2025. The CTMX-2051-101 Safety Review Committee convened on July 14, 2025, and supported continued study execution and enrollment.
CytomX is focused on developing novel conditionally activated, masked biologics localized to the tumor microenvironment. Their PROBODY® therapeutic platform aims to create safer, more effective therapies for cancer treatment. The company’s pipeline includes CX-2051, an ADC targeting EpCAM, and CX-801, a masked interferon alpha-2b PROBODY® cytokine.
Company Contact:
Chris Ogden
SVP, Chief Financial Officer
cogden@cytomx.com
Investor Contact:
Stephanie Ascher
Stephanie.Ascher@precisionaq.com
Media Contact:
Teri Dahlman
teri@redhousecomms.com
Source: CytomX Therapeutics, Inc.
